|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harris WP, Mostaghel EA, Nelson PS and
Montgomery B: Androgen deprivation therapy: progress in
understanding mechanisms of resistance and optimizing androgen
depletion. Nat Clin Pract Urol. 6:76–85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watson PA, Chen YF, Balbas MD, et al:
Constitutively active androgen receptor splice variants expressed
in castration-resistant prostate cancer require full-length
androgen receptor. Proc Natl Acad Sci USA. 107:16759–16765. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abbruzzese JL: Phase I studies with the
novel nucleoside analog gemcitabine. Semin Oncol. 23(Suppl 10):
S25–S31. 1996.
|
|
5
|
Muenchen HJ, Quigley MM, Pilat MJ, et al:
The study of gemcitabine in combination with other chemotherapeutic
agents as an effective treatment for prostate cancer. Anticancer
Res. 20:735–740. 2000.PubMed/NCBI
|
|
6
|
Cronauer MV, Klocker H, Talasz H, et al:
Inhibitory effects of the nucleoside analogue gemcitabine on
prostatic carcinoma cells. Prostate. 28:172–181. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morant R, Bernhard J, Maibach R, et al:
Response and palliation in a phase II trial of gemcitabine in
hormone-refractory metastatic prostatic carcinoma. Swiss Group for
Clinical Cancer Research (SAKK). Ann Oncol. 11:183–188. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rochman M, Malicet C and Bustin M:
HMGN5/NSBP1: a new member of the HMGN protein family that affects
chromatin structure and function. Biochim Biophys Acta. 1799:86–92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rochman M, Postnikov Y, Correll S, et al:
The interaction of NSBP1/HMGN5 with nucleosomes in euchromatin
counteracts linker histone-mediated chromatin compaction and
modulates transcription. Mol Cell. 35:642–656. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rochman M, Taher L, Kurahashi T, et al:
Effects of HMGN variants on the cellular transcription profile.
Nucleic Acids Res. 39:4076–4087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hock R, Furusawa T, Ueda T and Bustin M:
HMG chromosomal proteins in development and disease. Trends Cell
Biol. 17:72–79. 2007. View Article : Google Scholar
|
|
12
|
Shirakawa H, Rochman M, Furusawa T, et al:
The nucleosomal binding protein NSBP1 is highly expressed in the
placenta and modulates the expression of differentiation markers in
placental Rcho-1 cells. J Cell Biochem. 106:651–658. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shirakawa H, Landsman D, Postnikov YV and
Bustin M: NBP-45, a novel nucleosomal binding protein with a
tissue-specific and developmentally regulated expression. J Biol
Chem. 275:6368–6374. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang JW, Zhou LQ, Yang XZ, et al:
Up-regulated expression of a prostate cancer-related gene, NSBP1,
in prostate cancer cells. Basic Med Sci Clin. 24:393–397. 2004.
|
|
15
|
Wahafu W, He ZS, Zhang XY, et al: The
nucleosome binding protein NSBP1 is highly expressed in human
bladder cancer and promotes the proliferation and invasion of
bladder cancer cells. Tumour Biol. 32:931–939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ji SQ, Yao L, Zhang XY, Li XS and Zhou LQ:
Knockdown of the nucleosome binding protein 1 inhibits the growth
and invasion of clear cell renal cell carcinoma cells in vitro and
in vivo. J Exp Clin Cancer Res. 31:222012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han HJ, Russo J, Kohwi Y and
Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote
breast tumour growth and metastasis. Nature. 452:187–193. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Green J, Ikram M, Vyas J, et al:
Overexpression of the Axl tyrosine kinase receptor in cutaneous
SCC-derived cell lines and tumours. Br J Cancer. 94:1446–1451.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rizzolio F, Bione S, Sala C, et al:
Chromosomal rearrangements in Xq and premature ovarian failure:
mapping of 25 new cases and review of the literature. Hum Reprod.
21:1477–1483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang N, Zhou LQ and Zhang XY:
Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can
inhibit the in vitro and in vivo proliferation of prostate cancer
cells. Asian J Androl. 12:709–717. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang XY, Guo ZQ, Ji SQ, et al: Small
interfering RNA targeting HMGN5 induces apoptosis via modulation of
a mitochondrial pathway and Bcl-2 family proteins in prostate
cancer cells. Asian J Androl. 14:487–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang CJ, Li XS, Wahafu W, et al: Effect
of paclitaxel and gemcitabine on the expression of nucleosomal
binding protein 1 in bladder cancer cell line T24. Chin J Urol.
31:536–540. 2010.
|
|
23
|
Jiang N, Zhou LQ, Yao K and Huang C: The
experimental investigation of androgen independent prostate cancer
cell line inhibited growth in vivo by recombinant lentivirus of
small interfering RNA (siRNA) targeting NSBP1. Chin J Clinicians.
4:154–157. 2010.
|
|
24
|
Wang Y, Guo Z, Ge Q, Wang E, Zhang X and
Jin G: Preparation and characterization of RGD
tumour-homing-peptide-modified plasminogen K5. Biotechnol Appl
Biochem. 57:17–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rodriguez-Berriguete G, Fraile B,
Martinez-Onsurbe P, Olmedilla G, Paniagua R and Royuela M: MAP
kinases and prostate cancer. J Signal Transduct. 2012:1691702012.
View Article : Google Scholar
|
|
26
|
Buch-Hansen TZ, Bentzen L, Hansen S, et
al: Phase I/II study on docetaxel, gemcitabine and prednisone in
castrate refractory metastatic prostate cancer. Cancer Chemother
Pharmacol. 66:295–301. 2010. View Article : Google Scholar
|
|
27
|
Di Lorenzo G, Autorino R, Giuliano M, et
al: Phase II trial of gemcitabine, prednisone, and zoledronic acid
in pretreated patients with hormone refractory prostate cancer.
Urology. 69:347–351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garcia JA, Hutson TE, Shepard D, Elson P
and Dreicer R: Gemcitabine and docetaxel in metastatic,
castrate-resistant prostate cancer: results from a phase 2 trial.
Cancer. 117:752–757. 2011. View Article : Google Scholar
|
